Dihomo-γ-linolenic acid (all-cis-8,11,14-Eicosatrienoic acid) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system^[1][2][3]. IC50 & Target: Endogenous Metabolite In Vitro: Dihomo-γ-linolenic acid attenuates pro-inflammatory gene expression in human and mouse macrophages^[2].
Dihomo-γ-linolenic acid (50 μM; 24 hours) attenuates IFN-γ induced phosphorylation of STAT1 on serine 727^[2].
Dihomo-γ-linolenic acid attenuates IL-1β and TNF-α induced MCP-1 and ICAM-1 expression in human macrophages^[2].
Dihomo-γ-linolenic acid attenuates chemokine-driven monocytic migration and macrophage foam cell formation^[2].
Dihomo-γ-linolenic acid attenuates the expression of SR-A and CD36 in human macrophages^[2].
Dihomo-γ-linolenic acid modulates mitochondrial respiration^[2].
Dihomo-γ-linolenic acid modulates the properties of endothelial cells and VSMC^[2].
In Vivo: Dihomo-γ-linolenic acid (8 mg/mouse; i.g; twice a week; for 35 days) inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA^[3].